Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus TELDRIN.
ACTIDIL vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category C
Category C
Antihistamine
Antihistamine